Go to Contents Go to Navigation

Samsung BioLogics inks 3rd drug manufacturing deal with UCB

Welfare/Medicine 21:40 July 31, 2019

By Kim Han-joo

SEOUL, July 31 (Yonhap) -- Samsung BioLogics, a biopharmaceutical unit of South Korea's Samsung Group, said Wednesday that it has clinched a US$34 million drug manufacturing deal with Belgium-based pharmaceutical company UCB.

Under the deal, Samsung Biologics will manufacture UCB's anti-tau candidate to treat progressive supranuclear palsy. The drug candidate is currently in the third phase of clinical trials.

Samsung BioLogics said the deal's volume could expand to up to $148 million if the product succeeds and goes into production.

The deal is the third drug manufacturing contract between the two firms, following two deals signed in December 2017 for two other UCB products also under clinical development.

UCB has spent over 90 years innovating in the fields of neurology and immunology. The company recorded an annual revenue of 4.6 billion euros ($5 billion) last year.

This undated photo, provided by Samsung BioLogics, shows the company's headquarters. (PHOTO NOT FOR SALE) (Yonhap)


Send Feedback
How can we improve?
Thanks for your feedback!